Asset: Orally bioavailable selective THR-β small-molecule agonist
Development Stage: Phase I clinical stage (ongoing in China)
Indication: Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Key Asset Highlights:
（1）Exhibits high selectivity and potent agonistic activity against thyroid hormone receptor beta (THR-β), a key therapeutic target regulating hepatic lipid metabolism, inflammatory response and liver fibrosis progression.
（2）Effectively improves hepatic lipid accumulation, accelerates lipid catabolism, and alleviates persistent liver inflammation, targeting the core pathological drivers of MASH development and progression.
（3）Significantly ameliorates hepatic steatosis, inflammatory infiltration and early fibrotic lesions, providing a novel targeted therapeutic approach to reverse disease progression of MASH.
（4）Demonstrates prominent differentiated advantages with minimal systemic THR-α activation, effectively avoiding cardiovascular-related adverse effects and maintaining a superior therapeutic window.
（5）Possesses favorable oral pharmacokinetic properties and well-tolerated safety profiles, supporting continuous clinical dosing and long-term intervention for chronic metabolic liver diseases.
（6）Protected by a comprehensive and robust intellectual property portfolio, ensuring stable and exclusive domestic and global development and commercialization rights for MASH treatment.
If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
